NCT04478097

Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

A Randomized, Open, Single-dose, 3 Period Partial Replicated Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of CKD-333 or Co-administration of CKD-330 and D086 in Healthy Volunteers Under Fasting Conditions

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 51 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 54 Years
• Healthy volunteers: Accepted

Summary

This study is a randomized, open, single-dose, 3 period partial replicated crossover-design study to investigate the pharmacokinetic profiles and safety of CKD-333 in healthy volunteers.

Detailed description

To healthy subjects of fifty-one (51), following treatments are administered dosing in each period and wash-out period is a minimum of 14 days.

Conditions

• Cardiovascular Disease

Interventions

Type	Name	Description
DRUG	CKD-330 Tab. and D086 Tab.	1T
DRUG	CKD-333 Tab.	1T

Timeline

• Start date: 2020-07-14
• Primary completion: 2020-11-05
• Completion: 2021-01-01
• First posted: 2020-07-20
• Last updated: 2020-07-22

Locations

1 site across 1 country: South Korea